2023 Approvals
A Groundbreaking Approval: FDA Greenlights Truqap for Advanced Breast Cancer
What is Truqap prescribed for? Truquap is perscribed in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test